Dianthus Therapeutics, Inc.
DNTH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.12 | -0.11 | -0.01 | 0.22 |
| FCF Yield | -10.78% | -68.98% | -123.34% | -24.98% |
| EV / EBITDA | -6.95 | 1.63 | -0.31 | -8.54 |
| Quality | ||||
| ROIC | -28.62% | -28.31% | -39.48% | -7.31% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.92 | 0.85 | 1.02 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.95% | 24.17% | – | – |
| Free Cash Flow Growth | -111.75% | -26.57% | 51.95% | 5.63% |
| Safety | ||||
| Net Debt / EBITDA | 0.21 | 2.75 | 0.49 | 10.06 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 47.24 | 61.74 | 320.69 | 0.00 |